Efficient single-base genomic perturbations for next-gen screens, disease models, and therapeutic development.
With base editing you can avoid double-strand DNA breaks and achieve more precise genomic edits with improved cell viability and predictable outcomes. We offer multiple pathways to leverage the Pin-point™ base editing platform, depending on your program stage and goals.
With our Pin-point™ base editing CRO-style services, you can benefit from:
- More precise edits with clear and predictable mutations
- Avoid double strand DNA breaks
- High viability and cell health after editing
- Ideal for iPSCs and primary immune cells
- Save time and resources by leveraging our team’s expertise
In addition to our base editing services, we also offer Pin-point base editing reagents and licensing to the underlying patents and patent applications to provide broad access to base editing across the research and therapeutic market.
Contact us to discuss how we can help you accelerate your research with our base editing CRO services.
Therapeutic base editing preclinical development partnerships
For therapeutic developers advancing complex programs, we offer bespoke base editing development partnerships designed to support you from early architecture decisions through IND-enabling studies.
Collaborative platform optimization
Our team works alongside you to configure and optimize the Pin-point base editing platform for your indication, cell type, and translational objectives.
As part of this process, we may evaluate multiple editing configurations, deaminase variants, or guide designs to help identify the combination that delivers the efficiency, specificity, and functional performance your program requires. Leveraging our internal high-throughput screening capabilities, we generate data-driven insights to inform system selection and refinement before critical development milestones.
De-risk with strategic design support
Beyond initial evaluation, we support therapeutic editing strategy design, CBE or ABE configuration, multiplex editing approaches, and optimization workflows tailored for preclinical development. By addressing editing architecture decisions early, we help reduce technical uncertainty, improve reproducibility, and support downstream manufacturability and regulatory readiness.
Why partner with us
These partnerships combine licensable access to the Pin-point base editing platform with hands-on collaboration from the scientists who designed it. As a non-therapeutic developer, we are positioned solely to support your success, providing scientific expertise without competing for your downstream assets.
Let’s explore how a development partnership can help you accelerate and de-risk your base editing therapeutic program.
Cell line engineering services
The ability to make complex edits in a single editing experiment allows for the knockout of multiple genes in a single clonal cell line. This helps reduce experimental timelines and improve turnaround times, while also limiting cell viability challenges. Avoiding double strand DNA breaks reduces the risk of genomic aberrations that might otherwise compromise cell line performance. Utilize multiplexed gene knockout for improved disease modeling, target validation, and biological pathway analysis.
Partner with our in-house Preclinical Services team, who will guide you through the process and perform the experimental work for you, delivering the next-generation cell models you need for your next ground-breaking project.
Pooled tiled screening services
With the Pin-point platform, screens can be designed to tile guide RNAs across entire gene sequences, enabling the generation of precise C-to-T mutations. This facilitates the selection of guides for therapeutic applications, identification of critical amino acids in structure-function analysis, examination of ligand binding relationships in drug candidate screening, and validation of target identity among other applications.
Our team of scientists from our Preclinical Services team will work with you to generate high-quality, reproducible data that you can trust.
You may also be interested in
Pin-point base editing reagents are available for research use only and are not for diagnostic use or direct administration into humans or animals. The Pin-point base editing platform technology is available for clinical or diagnostic study and commercialization under a commercial license from Revvity.
